Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05046886 · ClinicalTrials.gov registry record · NA

Personalized Dietary Management in Type 2 Diabetes

A NA study of Type 2 Diabetes, sponsored by NYU Langone Health.

Active
Registry status
NA
Development phase
294
Enrollment target
1
Study location

NCT05046886 is a NA study of Type 2 Diabetes that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 294 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05046886, a NA study of Type 2 Diabetes, is active but no longer recruiting, sponsored by NYU Langone Health.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
294 participants
Enrollment target
1
Study location

Study Summary

In a randomized trial of 255 participants with early-stage T2D, participants will be randomized to 1 of 3 groups: Standardized, Personalized, or a Usual Care Control (UCC). In the first phase, participants will be randomized with equal allocation to these 3 groups. In the second phase (current phase), the remaining participants will be randomized with equal allocation to the Standardized and UCC groups.

Conditions Studied

Interventions

  • BEHAVIORAL Standardized
  • BEHAVIORAL Usual Care Control (UCC)
  • BEHAVIORAL Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR)

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 294 participants
Start Date 2021-12-14
Est. Completion 2025-11-30
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT05046886

The ClinicalTrials.gov registry entry for NCT05046886 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (73% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Standardized is the first listed.

NCT05046886 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05046886 about?

NCT05046886 is a clinical study titled "Personalized Dietary Management in Type 2 Diabetes". In a randomized trial of 255 participants with early-stage T2D, participants will be randomized to 1 of 3 groups: Standardized, Personalized, or a Usual Care Control (UCC). In the first phase, participants will be randomized with equal allocation to these 3 groups. In the second phase (current phase...

What is the current status of trial NCT05046886?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 294 participants. The study started on 2021-12-14. Estimated completion is 2025-11-30.

What conditions does trial NCT05046886 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT05046886?

The interventions under investigation include: Standardized (BEHAVIORAL), Usual Care Control (UCC) (BEHAVIORAL), Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05046886?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05046886 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.